Reversal of dopamine D2 receptor responses by an anandamide transport inhibitor

Journal of Neuroscience

Volumn 20, Issue 9, 2000, Pages 3401-3407

  Beltramo, Massimiliano ^a   Rodríguez De Fonseca, Fernando ^b   Navarro, Miguel ^b   Calignano, Antonio ^d   Gorriti, Miquel Angel ^b   Grammatikopoulos, Georgios ^c   Sadile, Adolfo G ^c   Giuffrida, Andrea ^d   Piomelli, Daniele ^a,c  

^a NEUROSCIENCES INSTITUTE   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE

Author keywords

AM404; Anandamide transport; Cannabinoid receptors; Dopamine receptors; Spontaneously hypertensive rats; Wistar Kyoto rats

Indexed keywords

ANANDAMIDE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; N (4 HYDROXYPHENYL) ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONYLETHANOLAMIDE; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; DOPAMINE RECEPTOR BLOCKING; DRUG MECHANISM; DRUG TRANSPORT; HOT PLATE TEST; HYPOKINESIA; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RAT; YAWNING;

EID: 0343133886     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.20-09-03401.2000     Document Type: Article

References (43)

1. Aspide R, Gironi Carnevale UA, Sergeant JA, Sadile AG (1998) Non-selecive attention and nitric oxide in putative animal models of attention-deficit and hyperactivity disorder. Brain Res 95:123-133.
2. Baraldi M, Benassi-Benelli A (1975) Apomorphine-induced penile erection in adult rats. Riv Farmacol Terapia 6:771-772.
3. Beltramo M, di Tomaso E, Piomelli D (1997a) Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one. FEBS Lett 403:263-267.
4. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997b) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094-1097.
5. Calignano A, La Rana G, Beltramo M, Makriyannis A, Piomelli D (1997a) Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur J Pharmacol 337:R1-R2.
6. Calignano A, La Rana G, Makriyannis A, Lin SY, Beltramo M, Piomelli D (1997b) Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur J Pharmacol 340:R7-R8.
7. Carey MP, Diewald L, Papa M, Gironi Carnevale UA, Pellicano MP, Esposito F, Sergeant JA, Sadile AG (1998) Differential distribution of D1 and D2 dopamine receptors in the target sites of the mesolimbic system in an animal model of ADHD. Behav Brain Res 94:173-185.
8. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594.
9. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87.
10. Désarnaud F, Cadas H, Piomelli D (1995) Anandamide amidohydrolase activity in rat brain microsomes: identification and partial characterization. J Biol Chem 270:6030-6035.
11. Deutsch DG, Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791-796.
12. Devane W, Hanus L, Breuer A, Pertwee R, Stevenson L, Griffin G, Gibson D, Mandelbaum D, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
13. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz J-C, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691.
14. Dourish CT, Herbert EN, Iversen SD (1989) Blockade of apomorphine-induced yawning in rats by the dopamine autoreceptor antagonist (+)-AJ76. Neuropharmacology 28:1423-1425.
15. Eilam D, Szechtman H (1989) Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol 161:151-157.
16. Esposito FJ, Gironi Carnevale UA, Diewald LM, Carey MP, Vallone D, Sadile AG (1999) Differential response of dopamine D-3 autorecep-tors to subchronic methylphenidate treatment in anterior forebrain sites of an animal model of hyperactivity and attention deficits. Soc Neurosci Abstr 25:848.
17. Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363.
18. Gorriti MA, Rodríguez de Fonseca F, Navarro M, Palomo T (1999) Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 365:133-142.
19. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
20. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB (1997) Accumulation of N-arachidonoylethanolamide (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 69:631-638.
21. Ledent C, Valverde O, Cossu G, Petitet F, Aubert J, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404.
22. Maillcux P, Vanderhaeghen JJ (1993) Dopaminegic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 61:1705-1712.
23. Matsuda LA, Bonner TI, Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327:535-550.
24. Melis MR, Argiolas A, Gcssa GL (1987) Apomorphine-induced penile erection and yawning: site of action in brain. Brain Res 415:98-104.
25. Navarro M, Hernández E, Munoz RM, del Arco I, Villanœa MA, Carrera MR, Rodríguez de Fonseca F (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. NcuroReport 8:491-496.
26. Okamoto K (1969) Spontaneous hypertension in rats. Int Rev Exp Pathol 7:227-270.
27. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180.
28. Picetti R, Saiardi A, Abdel Samad T, Bozzi Y, Baik JH, Borrelli E (1997) Dopamine D2 receptors in signal transduction and behavior. Crit Rev Neurobiol 11:121-142.
29. Piomelli D, Beltramo M, Giuffrida A, Stella N (1998) Endogenous cannabinoid signaling. Neurobiol Dis 5:462-473.
30. Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xiang-Qun Xie, Makriyannis A (1999) Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci USA 96:5802-5807.
31. Pryor GT, Larsen FF, Husain S, Braude MC (1978) Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats. Pharmacol Biochem Behav 8:295-318.
32. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannahinoid receptor. FEBS Lett 350:240-244.
33. Rodríguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF, Navarro M (1996) Corticotropin-releasing factor (CRF) antagonist [D-Phc12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 276:56-64.
34. Russell V (2000) The nucleus accumbens motor-limbic interface of the spontaneously hypertensive rat (SHR) as studied in-vitro by the superfusion slice technique. Neurosci Biobehav Rev 24:133-136.
35. Sadile AG (2000) Multiple evidence of a segmental defect in the anterior forebrain of an animal model of hyperactivity and attention deficit. Neurosci Biobehav Rev 24:161-169.
36. Sagvolden T, Pettersen MB, Larsen MC (1993) Spontaneously hypertensive rats (SHR) as a putative animal model of childhood hyperkinesis: SHR behavior compared to four other rat strains. Physiol Behav 54:1047-1055.
37. Sañudo-Peña MC, Walker JM (1998) Effects of intrapallidal cannabinoids on rotational behaviour in rats: interactions with the dopaminergic system. Synapse 28:27-32.
38. Sañudo-Peña MC, Patrick SL, Patrick RL, Walker JM (1996) Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. Neurosci Lett 206:21-24.
39. Sañudo-Peña MC, Force M, Tsou K, Miller AS, Walker JM (1998) Effects of intrastriatal cannabinoid on rotational behavior in rats: interactions with the dopaminergic system. Synapse 30:221-226.
40. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270:219-227.
41. Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411.
42. Yamada K, Furukawa T (1980) Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning. Psycopharmacology 67:39-43.
43. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780-5785.